David Hollander is joining Aerie Pharmaceuticals (NASDAQ: [[ticker:AERI]]) as chief research and development officer. Hollander most recently worked at Ora, where he was chief medical officer and senior vice president. His experience also includes more than a decade at Allergan (NYSE: [[ticker:AGN]]). Durham, NC-based Aerie has two FDA-approved glaucoma treatments: netarsudil (Rhopressa) and the netasudil and latanoprost combination therapy marketed as Rocklatan.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
